Here we examined the impact of IL-17 deficiency or blockade on the development of DN in vivo, and the effects of rIL-17 on kidney cells exposed to glucose in vitro, to demonstrate the involvement of IL-17A in DN and its role as a potential target for therapy. Here, IL17A is linked to liver dysplastic nodule.